NCT05105958View on ClinicalTrials.gov

Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 1, 2025

Study Completion Date

March 1, 2026

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Tideglusib

1000 mg/day per os

Trial Locations (5)

1205

University Hospital Geneva, Geneva

Unknown

University Hospital Bern, Bern

University Hospital Lausanne, Lausanne

Kantonsspital St. Gallen, Sankt Gallen

University Hospital Zurich, Zurich

All Listed Sponsors
collaborator

University of Lausanne Hospitals

OTHER

collaborator

University of Bern

OTHER

collaborator

Cantonal Hospital of St. Gallen

OTHER

collaborator

University Hospital, Geneva

OTHER

lead

University of Zurich

OTHER